Senses Disorder TRIZ Cases

Predicts treatment response by measuring CD8 protein density on autoreactive T cells, addressing inconsistent outcomes in autoimmune disease management.

Convergent synthesis segments complex quinoline construction, resolving linear reaction inefficiencies while maintaining therapeutic specificity.

A controlled release composition embeds microparticles within a matrix to stabilize active agents.

Pan-IAP antagonist compounds bind inhibitor of apoptosis proteins to overcome chemoresistance and promote cell death cascades.

Formula I heteroaryl compounds correct defective protein trafficking and folding to treat cystic fibrosis.

Biodegradable porous silicon particles deliver therapeutic agents through controlled diffusion and permeation mechanisms.

Alkynyl indazole derivative resolves low solubility and poor photostability of existing angiogenesis inhibitors, enabling stable liquid eye drop formulations.

A dihydropseudoerythromycin derivative reduces the 9-position double bond to form a saturated structure.

CD47 agonist peptides activate receptors to eliminate mononuclear phagocytes, resolving chronic inflammation in age-related macular degeneration.

Cell-specific promoters drive Connexin 26 expression in inner ear support cells, resolving hair cell toxicity while restoring hearing function.

Small molecule Ire1 modulators regulate protein folding capacity to prevent unfolded protein response induced cell death in disease contexts.

Merging RTK and DHFR inhibition into one molecule eliminates combination therapy toxicities while reducing tumor growth and metastasis effectively.

Hybrid hyaluronic acid complexes modulate viscosity while enhancing mucoadhesion, resolving discomfort from high molecular weight formulations.

Segmented PTX3 peptides inhibit FGF2-induced angiogenesis without affecting innate immunity.

Specific amino pyran derivatives inhibit DPP-IV selectively, reducing hypoglycemia and weight gain risks while maintaining glycemic control.

RNA interference targets junction components like p120 to stimulate proliferation of human corneal endothelial cells, reducing reliance on scarce donor tissue.

CGRP receptor antagonists block harmful peptide binding to provide neuroprotection independent of intraocular pressure reduction.

A multilayer cell composition combines limbal stromal and epithelial cells to restore corneal clarity.

Recombinant adeno-associated virus delivers fully human post-translationally modified anti-TNFα Fc fusion proteins to ocular tissues.

Anti-Factor Bb antibodies inhibit complement dysregulation by blocking membrane attack complex formation.

Chemical Formula 1 indole compound reduces reactive oxygen species and iron accumulation to overcome limited efficacy of existing ferrostatin-1 inhibitors.

Humanized anti-alpha5beta1 antibodies enhance binding affinity to treat cancer and age-related macular degeneration by inhibiting abnormal angiogenesis.

A lipocalin mutein binds the IL-4 receptor alpha chain to block cytokine interaction.

Segmented Fc domain fusion proteins reduce required protein load while maintaining therapeutic efficacy through enhanced Fc receptor binding.

Thieno[2,3-b]pyridine derivatives modulate mGluR1 and mGluR5 receptors to resolve selectivity challenges in CNS disorder treatments.

Lactococcus lactis secretes antigens at mucosal sites to activate regulatory T cells, resolving adverse effects from broad immunosuppressive drugs.

Modifying the indolin-2-one core enhances metabolic stability and selectivity, resolving trade-offs in therapeutic compound development.

Periodic dosing intervals of synthetic retinal derivatives restore visual acuity while minimizing toxicity risks associated with frequent administration.

Ixolaris selectively inhibits the TF/FVIIa complex to block angiogenesis, resolving the trade-off between anti-tumor efficacy and bleeding risk.

Sequential iron(III) salt addition selectively oxidizes alpha-tocotrienol chroman, minimizing non-alpha tocotrienol quinone impurities.

Baicalein analogs suppress inflammatory cytokine expression to rescue retinal ganglion cells from degeneration in glaucoma.

Substituted quinazoline and indole compounds inhibit Complement Factor B, addressing inadequate small molecule management of inflammatory responses.

Benzoxazine benzimidazole derivatives inhibit vanilloid receptor-1 activity to treat pain and inflammatory disorders without irritation.

Modifying substituents on the pyrrolopyridine core enhances antagonistic activity against TRPV1 receptors, addressing low efficacy in current compounds.

Segmented GEP peptides antagonize TNF signaling to modify rheumatoid arthritis pathology beyond cartilage.

Specific inhibitors and inducers reprogram somatic cells into corneal endothelial cell-like cells to restore transparency and fluid balance.

Mesembrenone merges PDE-4 and serotonin inhibition mechanisms to reduce side effects while improving therapeutic reliability.

SRPK1 inhibitors promote anti-angiogenic VEGF isoforms, avoiding frequent intraocular injections and adverse pressure effects.

Zinc chloride and polymeric compounds stabilize terpenoid content in aqueous ophthalmic compositions.

Biodegradable PLGA nanoparticles densely coated with hydrophilic polymers encapsulate dexamethasone sodium phosphate for sustained ocular release.

Chemical permeation enhancers enable sustained drug flux across the tympanic membrane using a phase-changing hydrogel matrix.

siRNA targets CYR61 mRNA to suppress angiogenesis, addressing inadequate gene expression reduction in diabetic retinopathy.

Novel himbacine derivatives act as dual thrombin receptor antagonists and cannabinoid CB2 inhibitors.